Regeneron, Sanofi rack up a PhIII asthma win for dupilumab; Verastem preps FDA app for duvelisib
→ Regeneron and Sanofi say their trial of Dupixent (dupilumab) hit the primary and key secondary endpoints in a Phase III asthma study. Their drug reduced the use of steroids by 70%, compared to 42% for the placebo arm. “Importantly, despite a reduction in oral corticosteroid use, dupilumab was associated with an improvement in lung function. This is the third study in which dupilumab has demonstrated a reduction in asthma attacks and improvement in lung function in a broad group of patients with uncontrolled asthma – this effect was most profound in patients with elevated markers of Type 2 allergic inflammation, such as an eosinophil count over 300,” said Regeneron chief scientist George Yancopoulos.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.